- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02038478
Allograft for Sickle Cell Disease and Thalassemia
Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Thalassemia
The design of the study incorporates the following features:
- This is a phase II study to determine the safety and therapeutic potential of a new transplant approach (disease-free survival, graft versus myeloma effect) and to evaluate its toxicity profile (immediate toxicity, graft-versus-host disease, graft rejection, mortality) in a patient population with severe congenital anemias.
- The patient cohort to be studied: Those patients with severe sickle cell disease and thalassemia who have risk factors for high mortality and morbidity related to their disease
- Transplant Conditioning Regimen - Immunosuppression without myeloablation: Patients will receive conditioning sufficient to allow donor lympho-hematopoietic engraftment without complete marrow ablation. If the graft is rejected, the patient will reconstitute autologous marrow function. We will use a combination of low dose irradiation, Alemtuzumab (Campath®), and sirolimus.
- Peripheral blood hematopoietic progenitor cell (PBPC) transplant: An unmanipulated peripheral blood stem cell collection from a filgrastim (G-CSF) stimulated HLA-matched donor should improve the chance of engraftment because of the high stem cell dose (5 x 106/kg CD34+ cells) and the presence of donor lymphocytes. To reduce the risk of GVHD, patients will receive sirolimus before and after the transplant. The sirolimus will be tapered as necessary to minimize any graft versus host disease while still maintaining adequate chimerism.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A human lymphocyte antigen (HLA)-matched sibling donor will receive filgrastim (G-CSF) 10 to16 µg/kg/d subcutaneously or intravenously for up to 6 days with apheresis collections of PBPC on day 5 (and day 6 if required). The product will be collected by leukophoresis with a goal of ≥ 10 x 106 CD34+ cells/kg, with a minimum of 5 x 106 CD34+ cells/kg.
The patient will receive a preparative regimen of Alemtuzumab to be infused on days -7 to -3, followed by 300 cGy TBI given as a single dose on day -2. Sirolimus at a dose of 5mg/day to maintain trough levels between 10-15ng/ml will be started on day -1. The PBPC graft targeted to deliver 10 x 106 CD34+ cells/kg (at minimum, 5 x 106 CD34+ cells/kg) will be infused on day 0 On days +14, +30, +60 and +100 the chimeric status of patients will be assessed by microsatellite analysis of the peripheral blood. More frequent monitoring may be required.
Sickle cell patients with pulmonary hypertension will meet with a Pulmonary Medicine Consult to determine appropriate management prior to SCT.
Patients with fever or suspected minor infection should await resolution of symptoms before starting the conditioning regimen.
Iron chelation must be discontinued > 48 hours before initiating the conditioning regimen.
Hydroxyurea must be discontinued one day prior to initiating the conditioning regimen.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Inclusion criteria - Recipient
Disease specific:
Sickle Cell Disease - Patients with sickle cell disease at high risk for disease related morbidity or mortality, defined by having irreversible end-organ damage (A, B, C,D, or E) or potentially reversible complication(s) not ameliorated by hydroxyurea (F):
A. Stroke defined as a clinically significant neurologic event that is accompanied by an infarct on cerebral MRI OR an abnormal trans-cranial Doppler examination (≥200m/s); OR
B. Sickle cell related renal insufficiency defined by a creatinine level ≥1.5 times the upper limit of normal and kidney biopsy consistent with sickle cell nephropathy OR nephrotic syndrome OR creatinine clearance < 50mL/min OR requiring peritoneal or hemodialysis. OR
C. Pulmonary hypertension as defined by tricuspid regurgitant jet velocity (TRV) of ≥ 2.5m/s at least 3 weeks after a vaso-occlusive crisis; OR
D. Recurrent tricorporal priapism defined as at least two episodes of an erection lasting ≥4 hours involving the corpora cavernosa and corpus spongiosa; OR
E. Sickle hepatopathy defined as EITHER ferritin >1000mcg/L OR direct bilirubin >0.4 mg/dL at baseline; OR
F. Any one of the below complications
- Vaso-occlusive crises
- Acute chest syndrome
- Osteonecrosis of 2 or more joints
Red cell alloimmunization
Thalassemia - Patients with thalassemia who have grade 2 or 3 iron overload, determined by the presence of 2 or more of the following:
• portal fibrosis by liver biopsy inadequate chelation history (defined as failure to maintain adequate compliance with chelation with desferroxamine initiated within 18 months of the first transfusion and administered subcutaneously for 8-10 hours at least 5 days each week) hepatomegaly of greater than 2 cm below the costochondral margin
Non-disease specific:
Ages ≥ 18 but ≤ 45
6/6 HLA matched family donor available
Ability to comprehend and willing to sign an informed consent, assent obtained from minors
Negative serum pregnancy test
Inclusion criteria - Donor
6/6 HLA identical family donor
Weight > 20 kg (in so far that the weight difference between recipient and donor does not exceed a reasonable likelihood of being able to obtain an adequate cell dose from the donor within two aphereses)
Fit to receive G-CSF and give peripheral blood stem cells (normal blood counts, normotensive, and no history of stroke)
Ability to comprehend and willing to sign an informed consent
Exclusion Criteria:
Exclusion criteria - Recipient
Any of the following would exclude the subject from participating
ECOG performance status of 3 or more or Lanksy performance status of <40
Diffusion capacity of carbon monoxide (DLCO) <50% predicted (corrected for hemoglobin and alveolar volume)
Baseline oxygen saturation of <85% or PaO2 <70
Left ventricular ejection fraction: <40% estimated by ECHO
Transaminases > 5x upper limit of normal for age
Evidence of uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms) within one month prior to starting the conditioning regimen
Major anticipated illness or organ failure incompatible with survival from PBSC transplant
Pregnant or lactating
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
Major ABO mismatch
Exclusion criteria - Donor
Any of the following would exclude the donor from participating
Pregnant or lactating
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
HIV positive
Hemoglobin S > 50%, or beta thalassemia intermediate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Transplantation Arm
Transplantation One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects. |
One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line.
This process takes approximately 30 minutes to 2 hours and is normally completely without side effects.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Success at One Year
Time Frame: Treatment Success at one year
|
This is defined as full donor type hemoglobin on hemoglobin electrrophoresis for patients with sickle cell disease and transfusion-independence for patients with thalassemia.
|
Treatment Success at one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Level of chierism required to maintain Graft Survival and hematologic normalcy
Time Frame: Measured on days 14, 30, 60 and 100
|
The chimeric status of patients will be measured on days +14, +30, +60, and +100 by microsatellite analysis of the peripheral blood.
|
Measured on days 14, 30, 60 and 100
|
Collaborators and Investigators
Investigators
- Principal Investigator: Prapti Patel, MD, UT Southwestern Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU 012013-015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease and Thalassemia
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
M.D. Anderson Cancer CenterWithdrawnSickle Cell Disease | Sickle Beta Thalassemia | Beta Thalassemia Major | Sickle Cell-SS Disease | Sickle Beta 0 Thalassemia | Sickle Beta Plus ThalassemiaUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationSickle Cell Anemia | Sickle Beta Thalassemia | Sickle Cell Thalassemia | Sickle Beta Zero Thalassemia | Sickle Cell Pain | Hbss | Hbsc | Sickle Cell Syndrome VariantUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingSickle Cell Disease | Sickle Cell Disorders | Hb-SS Disease | Hemoglobin S | Disease Sickle Cell Anemia | Hemoglobin Beta Thalassemia DiseaseUnited States
-
Kenneth Ataga, MDAugusta UniversityCompletedSickle Cell Anemia | Sickle - Beta Thalassemia
-
Ann & Robert H Lurie Children's Hospital of ChicagoNational Heart, Lung, and Blood Institute (NHLBI)RecruitingSickle Cell Disease | Sickle B+ Thalassemia | Sickle Beta Zero Thalassemia | Sickle Cell Hemoglobin CUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedSickle Cell Disease | Sickle B+ Thalassemia | Sickle Beta Zero Thalassemia | Sickle Cell Hemoglobin CUnited States
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Vertex Pharmaceuticals IncorporatedCRISPR TherapeuticsRecruitingHematologic Diseases | Genetic Diseases, Inborn | Sickle Cell Disease | Hemoglobinopathies | Sickle Cell Anemia | Thalassemia | Beta-ThalassemiaUnited States, Italy, Germany
Clinical Trials on Donor Stem Cell Transplantation
-
Hadassah Medical OrganizationUnknown
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Myeloproliferative Syndromes
-
Maastricht University Medical CenterUnknownMultiple MyelomaNetherlands
-
Children's Hospital of PhiladelphiaCompletedImmunodeficienciesUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Karolinska InstitutetMedical University of Vienna; Oslo University Hospital; Sahlgrenska University... and other collaboratorsTerminatedAcute Myeloid LeukemiaCanada, Austria, Sweden, Russian Federation, Norway
-
St. Jude Children's Research HospitalCompletedLymphoma, Non-Hodgkin | Hodgkin Disease | Chronic Myeloid Leukemia | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Myelodysplastic Syndrome (MDS) | Secondary AML | Juvenile Myelomonocytic Leukemia (JMML) | Secondary MDSUnited States
-
Northwestern UniversityTerminated
-
National Heart Institute, MexicoNational Center of Blood Transfusion Mexico.UnknownAcute Myocardial InfarctionMexico
-
General Hospital of Chinese Armed Police ForcesWithdrawn